Search
Innovative Ophthalmic Medication for Childhood Myopia Progression Seeks Domestic Market Approval
1 week ago /
Read about 0 minute
Author：小编
Sirophthalmic has announced that the National Medical Products Administration has approved the marketing application for NVK002, a Category 2 improved new drug. NVK002, a 0.02% atropine sulfate ophthalmic solution, is designed to combat the progression of myopia in children. Boasting a patented formula, NVK002 is preservative-free and boasts an estimated shelf life exceeding 24 months, positioning it as one of the most advanced atropine-based treatments globally for managing childhood myopia progression.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
